Agendia Responds to “Clinical Insights on MINDACT”
Dear Dr. Febbo, I recently received an email from Read More
New England Journal of Medicine Publishes MINDACT Trial Results Proving the Clinical Utility of MammaPrint in Assisting Physicians to Identify Early-Stage Breast Cancer Patients who can Safely Forgo Chemotherapy
46% of patients identified as high risk for recurrence according Read More
New Data Shows Agendia’s MammaPrint can Prevent Under and Over Treatment of Breast Cancer Patients with an Intermediate/Indeterminate OncotypeDx Recurrence Score
The PRospective study Of MammaPrint in breast cancer patients with Read More
Agendia Appoints Dr. Gabriel Hortobagyi as Chairman to their Medical Advisory Board
Company also announces new ASCO data presentation from the prospective Read More
MINDACT in the News
News, videos, social media and more about the recently released Read More
Agendia Appoints Dr. M. William Audeh to Chief Medical Officer
IRVINE, CA and AMSTERDAM – Agendia, Inc., a world leader Read More
Agendia’s MammaPrint First and Only Genomic Assay to Receive Level 1A Clinical Utility Evidence for Chemotherapy Benefit in Early Breast Cancer Patients
Clinical high-risk patients with a low-risk MammaPrint® result, including 48 Read More
Agendia to Highlight New MammaPrint Data at the 2016 European Breast Cancer Conference as a Prelude to Upcoming MINDACT Trial Findings
Company will also host a lunch symposium on genomic assays Read More
Agendia Statement in Response to Recent ASCO Guidelines on Biomarker Assay Use in Adjuvant Breast Cancer Care
Agendia is disappointed with the recent update to the American Read More
